Dietary and lifestyle habits among individuals living with chronic pain.
Sanofi eyes RSV antibody for its next blockbuster while Dupixent brings in record sales
Sanofi’s RSV antibody Beyfortus is still on track to reach blockbuster status this year as the company expands manufacturing capacity, according to remarks made Thursday